CRESCENT BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
CRESCENT BIOPHARMA, INC. (CBIO) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of -$1.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-26
- CRESCENT BIOPHARMA, INC. effective income tax rate reconciliation, other adjustments, amount for the quarter ending 2024-12-31 was $0.00.
- CRESCENT BIOPHARMA, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was -$1.85M.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 3 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month |
|---|---|---|
| 2025-12-31 | -$1.85M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |